Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Financials
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  05/16 11:36:38 am EDT
10402.00 GBX   +1.13%
11:26aAstraZeneca Expands License Deal With Drug Discovery Startup to Develop Cancer Therapies
MT
05:28aAstraZeneca Expands Oncology Collaboration With Proteros
MT
04:58aFTSE 100 rises as healthcare, resource-linked gains offset China jitters
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 132 331131 461181 878198 415--
Enterprise Value (EV)2 144 340143 328206 261220 925216 466210 663
P/E ratio 97,9x41,0x1 468x36,8x23,9x18,6x
Yield 2,78%2,80%2,44%2,34%2,46%2,55%
Capitalization / Revenue 5,43x4,94x4,86x4,54x4,24x3,87x
EV / Revenue 5,92x5,38x5,51x5,05x4,63x4,10x
EV / EBITDA 21,6x17,2x27,2x15,4x12,5x10,4x
Price to Book 10,00x8,41x4,24x4,83x4,41x3,88x
Nbr of stocks (in thousands) 1 311 9131 312 6601 549 1591 549 464--
Reference price (USD) 101100117126126126
Announcement Date 02/14/202002/11/202102/10/2022---
1 GBP in Million
2 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 24 38426 61737 41743 73746 78851 325
EBITDA1 6 6868 3117 58614 34417 25620 269
Operating profit (EBIT)1 6 4367 3409 92814 06716 38618 977
Operating Margin 26,4%27,6%26,5%32,2%35,0%37,0%
Pre-Tax Profit (EBT)1 1 5483 916-2655 2549 88712 384
Net income1 1 3353 1961125 3078 20010 374
Net margin 5,47%12,0%0,30%12,1%17,5%20,2%
EPS2 1,032,440,083,425,266,76
Dividend per Share2 2,802,802,872,943,103,21
Announcement Date 02/14/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 9 86612 01111 39010 58910 74811 246
EBITDA1 1 1141 9002 1874 6303 2514 419
Operating profit (EBIT)1 2 2813 3183 9613 4103 5253 247
Operating Margin 23,1%27,6%34,8%32,2%32,8%28,9%
Pre-Tax Profit (EBT)1 -2 001-6365539421 2971 444
Net income1 -1 652-3473861 3751 5312 063
Net margin -16,7%-2,89%3,39%13,0%14,2%18,3%
EPS2 -1,10-0,220,250,690,931,25
Dividend per Share ------
Announcement Date 11/12/202102/10/202204/29/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 12 00911 86724 38322 50918 05112 248
Net Cash position1 ------
Leverage (Debt / EBITDA) 1,80x1,43x3,21x1,57x1,05x0,60x
Free Cash Flow1 1 9903 8384 8727 91310 71412 818
ROE (Net Profit / Equities) 35,6%36,7%27,5%25,6%28,4%30,4%
Shareholders' equity1 3 7528 70440720 70428 83434 176
ROA (Net Profit / Asset) 2,19%4,99%8,77%5,23%9,73%11,6%
Assets1 61 01564 0531 277101 50484 26389 669
Book Value Per Share2 10,111,927,726,028,532,5
Cash Flow per Share2 2,283,664,187,249,2310,5
Capex1 9799611 0912 0272 0152 148
Capex / Sales 4,01%3,61%2,92%4,63%4,31%4,18%
Announcement Date 02/14/202002/11/202102/10/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Analysis
AstraZeneca says its COVID shot still has role despite global glut
Key data
Capitalization (GBP) 162 166 903 600
Capitalization (USD) 198 604 954 625
Net sales (USD) 37 417 000 000
Number of employees 83 100
Sales / Employee (USD) 450 265
Free-Float 96,4%
Free-Float capitalization (GBP) 156 292 769 627
Free-Float capitalization (USD) 191 410 933 618
Avg. Exchange 20 sessions (USD) 20 254 393 167
Average Daily Capital Traded 12,5%
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA